In the CANTOS trial, canakinumab (an IL-1β targeting antibody) reduced the number of major cardiovascular events in CKD patients with a prior myocardial infarction and high inflammatory (CRP) status [31]. This evidence concerns the gene IL1B and myocardial infarction.